College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United Ststes.
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Oncologist. 2024 Jul 5;29(7):e918-e921. doi: 10.1093/oncolo/oyae083.
Prescription drug costs within oncology remain a challenge for many patients with cancer. The Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022, aiming to provide transparently priced medications at reduced costs. In this study, we sought to describe the potential impact of MCCPDC on Medicare Part-D oncology spending related to cancer-directed (n = 7) and supportive care (n = 26) drugs. We extracted data for drug-specific Part-D claims and spending for 2021. Using 90-count purchases from MCCPDC, we found potential Part-D savings of $857.8 million (91% savings) across the 7 cancer-directed drugs and $28.7 million (67% savings) across 21/26 (5/26 did not demonstrate savings) supportive care drugs. Collectively, our findings support that alternative purchasing models like MCCPDC may promote substantial health care savings.
肿瘤患者的处方药费用仍然是许多患者面临的挑战。马克·库班成本加成药品公司（MCCPDC）于 2022 年成立，旨在以降低的成本提供透明定价的药物。在这项研究中，我们试图描述 MCCPDC 对医疗保险部分-D 与癌症定向（n = 7）和支持性护理（n = 26）药物相关的肿瘤支出的潜在影响。我们提取了 2021 年特定药物的部分-D 索赔和支出数据。使用 MCCPDC 的 90 计数购买，我们发现 7 种癌症定向药物的潜在部分-D 节省 8.578 亿美元（91%的节省），26 种/21 种（5/26 种没有显示节省）支持性护理药物的节省 2870 万美元（67%的节省）。总的来说，我们的研究结果表明，像 MCCPDC 这样的替代采购模式可能会促进大量的医疗保健储蓄。
